One of the unmet needs in Parkinson’s disease is the lack of reproducible high-throughput cellular models to study α-synuclein biology. In this video, Dr. Folkert Verkaar, Team Leader in Biology at Charles River Leiden, describes the development of a high-content analysis-based assay to measure α-synuclein aggregation in a terminally differentiated cell line. The α-synuclein aggregation assay has been miniaturized to a 384-well plate-based automated assay that was used to test 1,000 compounds as a proof of principle. Learn More
Need help planning your study? Contact us
- View our recent webinar series on predictive assays and clinically relevant biomarkers for Parkinson’s disease.
- View our video blog from SfN 2017 on recent advances in Parkinson’s disease drug discovery.
- Download our scientific poster on the alpha-synuclein aggregation assay that was presented at SfN 2017.